Brentuximab Vedotin (Adcetris) for Peripheral T-cell Lymphoma


( Last Updated : June 19, 2020)
Generic Name:
Brentuximab Vedotin
Project Status:
Complete
Therapeutic Area:
peripheral T-cell lymphoma (PTCL)
Manufacturer:
Seattle Genetics, Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0199-000
NOC Date:

Details


Strength:
50 mg / vial
Tumour Type:
Lymphoma
Indications:
Peripheral T-cell Lymphoma (PTCL)
Funding Request:
For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.